92 completed, 30 terminated, 10 withdrawn, 9 active not recruiting. 164 Phase 2, 39 Phase 1, 2 Phase 3.
Follow Mycosis Fungoides: new trials by email Literature Review of Mycosis Fungoides trials Research Report on Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Topical JAK-Inhibition of Early-Stage CTCL delgocitinib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 2 | Not yet recruiting | Aarhus University Hospital | 15 | 2026-09-01 | 2026-08-26 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma Benvitimod Cream, Placebo cream - Cutaneous T-Cell Lymphoma, Mycosis Fungoides (MF) | Phase 2 | Not yet recruiting | Peking University First Hospital | 35 | 2026-07-01 | 2026-06-22 |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides A-dmDT390-bisFv(UCHT1), Vorinostat - Mycosis Fungoides | Phase 2 | Withdrawn | Virogen Biotechnology Inc. | 2026-05-01 | 2026-05-18 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Riluzole, Placebo - Breast Cancer, Sarcoma | Phase 2 | Recruiting | University of California, Irvine | 75 | 2024-12-02 | 2026-07-14 |
| BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma Cemiplimab - Mycosis Fungoides | Phase 1 / Phase 2 | Withdrawn | AHS Cancer Control Alberta | 2024-12-01 | 2025-06-27 | |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL Hypericin, Mechlorethamine Topical Gel - Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 2 | Completed | Soligenix | 10 | 2023-12-05 | 2025-08-20 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Completed | Ellen Kim, MD | 10 | 2023-08-21 | 2026-02-09 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 34 | 2022-10-19 | 2026-09-02 |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Brentuximab vedotin - Mycosis Fungoides | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2022-10-13 | 2026-07-29 |
| PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma Hypericin - Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 2 | Completed | Soligenix | 9 | 2022-05-09 | 2023-06-07 |
| REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) chlormethine gel - Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB) | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 2 | 2022-03-29 | 2023-11-09 |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy - Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Suspended | Myeloid Therapeutics | 40 | 2021-12-15 | 2023-11-13 |
Showing 20 of 164. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (131) · Sezary Syndrome (125) · Lymphoma, Non-Hodgkin (70) · Leukemia, Lymphocytic, Chronic, B-Cell (68) · Lymphoma, B-Cell, Marginal Zone (68) · Lymphoma, Follicular (68) · Lymphoma, Large B-Cell, Diffuse (67) · Lymphoma, Mantle-Cell (65) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (64) · Hodgkin Disease (62) · Burkitt Lymphoma (59) · Lymphoma, Large-Cell, Immunoblastic (59) · Lymphoma (57) · Lymphoma, Large-Cell, Anaplastic (54)
Hemic and Lymphatic Diseases (164) · Neoplasms by Histologic Type (164) · Immune System Diseases (162) · Immunoproliferative Disorders (162) · Lymphatic Diseases (162) · Neoplasms (158) · Lymphoproliferative Disorders (154) · Lymphoma, T-Cell (147) · Lymphoma (107) · Lymphoma, Non-Hodgkin (94) · Hematologic Diseases (82) · Leukemia, Lymphoid (80) · Pathological Conditions, Signs and Symptoms (73) · Disease Attributes (72) · Pathologic Processes (72)
fludarabine phosphate (23) · Mycophenolic Acid (19) · Peripheral Blood Stem Cell Transplantation (18) · Tacrolimus (17) · Cyclophosphamide (16) · Whole-Body Irradiation (16) · Cyclosporine (13) · Busulfan (12) · Methotrexate (12) · Antilymphocyte Serum (11) · Radiotherapy (9) · Rituximab (7) · pembrolizumab (7) · Alemtuzumab (6) · Bexarotene (6)
Fred Hutchinson Cancer Center (19) · National Cancer Institute (NCI) (13) · Northwestern University (10) · M.D. Anderson Cancer Center (9) · Mayo Clinic (8) · European Organisation for Research and Treatment of Cancer - EORTC (6) · City of Hope Medical Center (5) · Case Comprehensive Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Roswell Park Cancer Institute (3) · UNC Lineberger Comprehensive Cancer Center (3) · Virogen Biotechnology Inc. (3) · BioCryst Pharmaceuticals (2) · Genmab (2) · Herbert Irving Comprehensive Cancer Center (2)
United States (135) · Italy (13) · France (11) · Germany (9) · Switzerland (9) · Belgium (7) · United Kingdom (7) · Spain (6) · Australia (5) · Austria (5) · Canada (4) · China (2) · Finland (2) · Japan (2) · Poland (2)
Timothy M. Kuzel, MD (4) · Brenda Sandmaier (3) · Madeleine Duvic, MD (3) · Ajay Gopal (2) · Alison Moskowitz, MD (2) · David G. Savage, MD (2) · David Maloney (2) · Diana M. Escolar, MD, FAAN (2) · Larisa Geskin, MD (2) · Robert Knobler (2) · Ronald Levy (2) · Steven M. Horwitz, MD (2) · Stuart Lessin, M.D. (2) · Thomas C. Shea, MD (2)
PMID 32632956, PMID 32499241, PMID 22045986, PMID 25795722, PMID 35536441, PMID 12543862, PMID 15107815, PMID 17515522, PMID 18327587, PMID 18645136, PMID 19170225, PMID 19199905, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20697067, PMID 21135857, PMID 21355097, PMID 22981498, PMID 23045580, PMID 23069814, PMID 24241210, PMID 24285015, PMID 24335103, PMID 24948692, PMID 25891346, PMID 25921059, PMID 26195720, PMID 26210442, PMID 26213141, PMID 26764356, PMID 28199478, PMID 28264616, PMID 28314788, PMID 28980004, PMID 31532724, PMID 31689242, PMID 32269142, PMID 33072126, PMID 33085815, PMID 33236943, PMID 34091453, PMID 34795254, PMID 35122614, PMID 35750419, PMID 37327113, PMID 37802679
P30CA015704 (9), 2018 (4), P30CA015083 (4), P01CA018029 (3), P30CA008748 (3), P30CA043703 (3), P01CA078902 (2), P30CA016086 (2), P30CA016672 (2), P30CA033572 (2), P30CA060553 (2), U01CA154967 (2), 2004 (1), 2016 (1), 2017 (1)